In CommitteeFiled Jun 2, 2026
Sponsor: Rep. Moolenaar, John R. [R-MI-2] (R)
Latest Action
Referred to the House Committee on Financial Services.
Jun 2, 2026
Summary
The BINSA Act adds biotechnology—pharmaceuticals, biologics, and related therapeutic research—to the list of technologies that can be restricted or reported under the Defense Production Act. It requires the Treasury to define the biotech sector and to focus on licensing, joint‑venture and equity deals with Chinese firms. The goal is to prevent U.S. capital and intellectual property from strengthening China’s biotech capabilities, which lawmakers view as a strategic risk.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when HR 9102 changes status, plus AI-powered summaries and stage predictions.
Sign up free